Revised July 2012
Division of Basic Neuroscience & Behavior Research (DBNBR)
| Name | Interests |
|---|---|
| Beth Babecki | Institutional, individual and career development training grants. |
| Mark Caulder | Human genetics of drug dependence and addiction, candidate gene expression, next generation sequencing, genome-wide association studies. |
| Christine Colvis, Ph.D. | Proteomics, technology development, neuroscience and co-morbid conditions such as HIV and hepatitis C. |
| Jonathan D. Pollock, Ph.D. | Molecular genetics of substance abuse, molecular genetics of synaptic plasticity and memory, model organisms. |
| Joni L. Rutter, Ph.D. | Human and population genetics, pharmacogenetics, gene x gene, gene x environment interactions, molecular genetics of drug addiction and addiction vulnerability, and ELSI issues. |
| John Satterlee, Ph.D. | Model organisms and behavioral genetics, RNAi and microRNAs, epigenetics, signal transduction. |
| Karen Skinner, Ph.D. | Systems biology, data integration, multilevel modeling, biomedical computation. |
| Susan Volman, Ph.D. | Behavioral genetics of drug abuse and of co-occuring disorders in animal models. |
| Da-yu Wu, Ph.D. | Neural development, molecular genetics, animal models, and RNAi. |
Division of Clinical Neuroscience, Development and Behavioral Research (DCNBR)
| Name | Interests |
|---|---|
| Harold Gordon, Ph.D. | Human genetics of drug abuse vulnerability and resilience, risks associated with early or chronic stress, interactions between drug use and sleep disturbances/circadian rhythms. |
| Steven Grant | Brain imaging and radiotracer development, cognitive neuroscience, decision-making. |
| Karen Sirocco, Ph.D. | Gene by environment by development interactions that impact neurobehavior, cognition, and drug use resilience or vulnerability. |
Division of Epidemiology, Services, and Prevention Research (DESPR)
| Name | Interests |
|---|---|
| Kevin P. Conway, Ph.D. | Familial and genetic vulnerability, phenotypic heterogeneity of drug use disorders, environmental influences on the expression of liability, comorbid disruptive behavior problems, and temperament and personality, particularly behavioral disinhibition. |
| Naimah Weinberg, M.D. | Gene by environment by development interplay in the etiology and trajectories of substance use disorders and comorbid psychiatric conditions, and related methodologic studies. |
Division of Pharmacotherapies and Medical Consequences of Abused Drugs (DPMCDA)
| Name | Interests |
|---|---|
| Jag H. Khalsa, Ph.D. | Genetics of metabolic (including nutritional) & endocrine disorders of drug abuse, co-occurring infections (HIV, hepatitis C, TB, STDs); genetics of drug-drug interactions among antiretrovirals, drugs of abuse and addiction treatment medications. |
| Iván D. Montoya, M.D., M.P.H. | Pharmacogenetics of the safety and efficacy of medications approved or being investigated for the treatment of substance use disorders. |
| Amrat P. Patel, Ph.D. | Medication development, neurotransmitter transporter pharmacology, pharmacokinetics, and metabolism. |
Intramural Research Program
| Name | Interests |
|---|---|
| George Uhl, M.D. Ph.D. | Genetics and molecular neurobiology of addictions; association genome scanning; pooled association genome scanning. |
NIDA Clinical Trials Network
| Name | Interests |
|---|---|
| Raul Mandler, M.D. | Pharmacotherapy clinical investigation and translational medicine |
NIDA Office of AIDS Research Program
| Name | Interests |
|---|---|
| Diane M. Lawrence, Ph.D. | HIV/AIDS, neuropathogenesis, inflammation, neuroimmunology, neuron-glia interactions. |
Office of Extramural Affairs
| Name | Interests |
|---|---|
| Mark R. Green, Ph.D. | Peer/grant review. |
| Meenaxi Hiremath, Ph.D. | Grants receipt and referral. |
| Mark Swieter, Ph.D. | Training and career development and peer/grant review. |
Featured Publication
2010 Strategic Plan
Outlines NIDA’s drug abuse and addiction research strategic priorities for the next 5 years, focusing on prevention, treatment, HIV/AIDS, and other cross-cutting issues.